|
1
|
Jannin A, Penel N, Ladsous M, Vantyghem MC
and Do Cao C: Tyrosine kinase inhibitors and immune checkpoint
inhibitors-induced thyroid disorders. Crit Rev Oncol Hematol.
141:23–35. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mittendorf EA, Zhang H, Barrios CH, Saji
S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, et al:
Neoadjuvant atezolizumab in combination with sequential
nab-paclitaxel and anthracycline-based chemotherapy versus placebo
and chemotherapy in patients with early-stage triple-negative
breast cancer (IMpassion031): A randomised, double-blind, phase 3
trial. Lancet. 396:1090–1100. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schmid P, Cortes J, Pusztai L, McArthur H,
Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, et al:
Pembrolizumab for early triple-negative breast cancer. N Engl J
Med. 382:810–821. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schmid P, Adams S, Rugo HS, Schneeweiss A,
Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, et al:
Atezolizumab and nab-paclitaxel in advanced triple-negative breast
cancer. N Engl J Med. 379:2108–2121. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cortes J, Cescon DW, Rugo HS, Nowecki Z,
Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, et
al: Pembrolizumab plus chemotherapy versus placebo plus
chemotherapy for previously untreated locally recurrent inoperable
or metastatic triple-negative breast cancer (KEYNOTE-355): A
randomised, placebo-controlled, double-blind, phase 3 clinical
trial. Lancet. 396:1817–1828. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brahmer JR, Lacchetti C, Schneider BJ,
Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner
JM, Ginex P, et al: Management of immune-related adverse events in
patients treated with immune checkpoint inhibitor therapy: American
Society of clinical oncology clinical practice guideline. J Clin
Oncol. 36:1714–1768. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Postow MA, Sidlow R and Hellmann MD:
Immune-Related adverse events associated with immune checkpoint
blockade. N Engl J Med. 378:158–168. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
NCCN Clinical Practice Guidelines in
Oncology, . (NCCN Guidelines®). Breast Cancer. (version
4.2020). NCCN; May 8–2020
|
|
9
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Adams S, Schmid P, Rugo HS, Winer EP,
Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, et al:
Pembrolizumab monotherapy for previously treated metastatic
triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086
study. Ann Oncol. 30:397–404. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai
L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, et al:
Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic
complete response in women with early-stage breast cancer: An
analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial.
JAMA Oncol. 6:676–684. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weber JS, Hodi FS, Wolchok JD, Topalian
SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, et
al: Safety profile of nivolumab monotherapy: A pooled analysis of
patients with advanced melanoma. J Clin Oncol. 35:785–792. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Delivanis DA, Gustafson MP, Bornschlegl S,
Merten MM, Kottschade L, Withers S, Dietz AB and Ryder M:
Pembrolizumab-Induced Thyroiditis: Comprehensive clinical review
and insights into underlying involved mechanisms. J Clin Endocrinol
Metab. 102:2770–2780. 2017. View Article : Google Scholar : PubMed/NCBI
|
